Archives

  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • Moniliformin br Results br The flow of participants

    2019-11-12


    Results
    The flow of participants through this study is presented in Fig. 1. There was an overrecruitment to the study with 104 in the intervention arm and 103 in the control arm, greater than the 99 planned per arm. A decision was made to include all participants because there was capacity to do so. No partici-pants were removed from the waiting list control arm for previous use of the Move More Pack.
    The baseline characteristics of the participants (Table 1) in the intervention and control arms were broadly similar; however, physical activity was higher in the control arm (Table 2). The baseline physical activity level for the trial sample as a whole was slightly higher than that of the general cancer Moniliformin in England with 25.1% classified as active compared with 23.0%.4 Data are not available on the physical activity levels of cancer survivors from across the UK.
    The age profile of the trial sample is younger than that of the UK cancer population, with only 23.7% of participants older than 65 years compared with 63.0% of all UK cancer survivors.44 The trial sample is overrepresentative of females with 73.9% compared with 59.1% in the UK cancer popula-tion.44 Data are not available at a UK level on the prevalence of cancer in people from a black or minority ethnic group;45 however, with 14% of people in England and Wales identi-fied as black or from a minority ethnic group, it is possible that the trial sample is underrepresented with only 3.4%.46 It is estimated that 27.6% of UK cancer survivors are living with breast cancer, 13.2% with prostate cancer and 11.6% with colorectal cancer.45 This compares to 38.2%, 6.8% and 13.0% of the trial sample for breast, prostate and colorectal cancer, respectively.
    All trial participants received the intervention as planned. Sadly, one person in the control arm died between the 12-week and 24-week time points not related to the interven-tion. A log of participant issues was maintained throughout the study; however, no issues or adverse events were re-ported. All participants were offered a debriefing phone call at the end of the study; however, no participants took up hypothesis offer.
    Physical activity
    The intervention arm reports a mean physical activity improvement score of 9.58 (standard deviation [SD] ΒΌ 23.14) 
    Self-efficacy
    Health-related quality of life
    Fig. 1 e Flow of participants through the trial.
    Table 1 e Participant baseline characteristics.
    Gender
    Age in years
    Ethnicity
    Black or UK minority ethnic group 4 (3.8)
    Cancer
    Time since diagnosis
    Treatment status
    Not started treatment 3 (2.9)
    Cancer status
    Treated but cancer still present 13 (12.5)
    Cancer has come back since treatment 6 (5.8)
    Cancer present, no treatment received 3 (2.9)
    Table 2 e Change in physical activity, self-efficacy and health-related quality of life scores [mean (standard deviation)].
    Intervention
    Control
    Baseline 12 weeks 24 weeks
    Baseline 12 weeksa 24 weeks
    a The Move More Pack (intervention) was introduced to the control arm participants at 12 weeks.
    b
    Significant difference between intervention and control arms e P<0.05.
    c Significant difference within group from baseline to 12 weeks e P <0.001.
    d
    Significant difference within group from baseline to 24 weeks (assessment in the intervention arm only) e P <0.001.
    e
    f
    Significant difference within group from baseline to 12 weeks e P <0.05.
    g
    Significant difference within group from baseline to 12 weeks e P <0.01.
    Cost-consequence analysis
    The costs for the Move More Pack (intervention) and the standard letter recommendation (control) are presented in Table 3. The cost-consequence analysis is presented for a 12-week period. The 12-week outcomes for physical activity, self-efficacy and HRQOL are presented in Table 2.